Solutions to your working problems

Article

Breaking news from Day 2 of ESCRS

Improving retinal examination speed and efficiency
Canon Europe, revealed its new CX-1, a world first in retinal imaging technology for the first time at this year's ESCRS Congress.

Three steps to better toric surgery
New at congress, Zeiss Toric Solution is a combination of tools to allow physicians to implant and align toric lenses faster and easier.

Megatron S4 from Geuder delivers flexibility and mobility
Geuder has launched the Megatron S4 system, an upgrade on the company’s Megatron S3, which has sold 700 units worldwide since its launch in 2001. “The launch of the S4 marks the successful end of about three years work,”said Dirk Mittnacht, product manager systems for Geuder.

More news from the congressA quartet of solutions for surgeonsAt the sharp endAn all in one optical biometer

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
A phone with the Alcon logo on it, visible against another digital background. Concept image for Alcon company acquisition of Aurion Biotech. Image credit: ©Mojahid Mottakin – stock.adobe.com

Alcon acquires majority interest in cell therapy company Aurion Biotech, provides operational updates

Martin David Harp
March 27th 2025
Article

AURN001 is Aurion Biotech's clinical-stage allogeneic cell therapy asset for corneal oedema secondary to corneal endothelial disease

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A woman with neck pain and glasses at a computer. Concept image for dry eye and fibromyalgia. Image credit: ©peopleimages.com – stock.adobe.com

Association between dry eye, ophthalmic structures and fibromyalgia syndrome

Lynda Charters
March 26th 2025
Article

The authors examined vascular and neural structures in the eye, assessing the foveal avascular zone and choroidal thickness

A person typing on a computer keyboard as icons representing documents and papers. Research paper publication concept image. Image credit: ©cherdchai – stock.adobe.com

Nanoscope Therapeutics publishes clinical results of MCO-010 findings for patients with retinitis pigmentosa

Martin David Harp
March 26th 2025
Article

The synthetic opsin was packaged into an optimised AAV2 gene therapy vector that targets human retinal bipolar cells.

European Union flags outside the European Commission, where the Alcon Clareon Vivity IOL received a CE mark. Image credit: ©Arcady – stock.adobe.com

Alcon Clareon Vivity IOL receives CE mark, European commercialisation announced

Hattie Hayes
March 25th 2025
Article

The lens will be available with the Monarch IV manual delivery system in Q2 and the AutonoMe Automated Pre-Loaded Delivery System in Q3

The Moorfields Eye Hospital NHS Foundation Trust logo courtesy NHS Foundation Trust. Insitro logo courtesy Insitro. Lock and data point assets created with Canva.

Moorfields Eye Hospital INSIGHT research hub will collaborate with artificial intelligence development company Insitro

Hattie Hayes
March 24th 2025
Article

The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases

© 2025 MJH Life Sciences

All rights reserved.